D. Boral Capital Reiterates Buy Rating for Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports. They presently have a $9.00 price target on the stock.

Several other equities analysts also recently issued reports on IVVD. Morgan Stanley reduced their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Invivyd in a report on Monday, February 24th. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $7.89.

Invivyd Stock Performance

Shares of NASDAQ:IVVD opened at $0.74 on Thursday. The business’s fifty day moving average price is $0.98 and its two-hundred day moving average price is $0.87. The stock has a market cap of $88.28 million, a PE ratio of -0.38 and a beta of 0.09. Invivyd has a one year low of $0.35 and a one year high of $4.74.

Invivyd (NASDAQ:IVVD) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.10. The company had revenue of $13.80 million for the quarter, compared to analysts’ expectations of $13.57 million. As a group, equities research analysts predict that Invivyd will post -1.64 earnings per share for the current fiscal year.

Insider Buying and Selling at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 75,776 shares of the company’s stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.45, for a total transaction of $34,099.20. Following the completion of the sale, the director now directly owns 3,492,498 shares in the company, valued at $1,571,624.10. This represents a 2.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold a total of 246,138 shares of company stock worth $120,902 in the last quarter. 17.90% of the stock is owned by insiders.

Institutional Trading of Invivyd

A number of institutional investors have recently modified their holdings of IVVD. Jane Street Group LLC lifted its position in Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after buying an additional 87,358 shares in the last quarter. Barclays PLC lifted its holdings in shares of Invivyd by 7.8% during the 4th quarter. Barclays PLC now owns 127,180 shares of the company’s stock valued at $56,000 after acquiring an additional 9,207 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in Invivyd during the 4th quarter worth $74,000. JPMorgan Chase & Co. increased its holdings in Invivyd by 644.1% in the 4th quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after purchasing an additional 222,375 shares in the last quarter. Finally, Two Sigma Advisers LP increased its holdings in Invivyd by 1,276.5% in the 4th quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock valued at $135,000 after purchasing an additional 282,100 shares in the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.